Our CAR T-cells specific to targets expressed in a vast majority of tumor indications
NKG2D-based CAR T-cells
- NKG2D is an activating receptor expressed on natural killer (NK) cells and some T-cell subsets (CD8+ T cells NKT, γδT cells). In its normal situation, NK cells use NKG2D to scan the whole body for the presence of these stress signals on cells and tissues which could be indicative of a virus or bacterial infection, or malignant transformation.
- NKG2D binds to eight stress-induced ligands (MICA, MICB, ULBPs 1-6) over-expressed on tumor cells in most solid tumors and hematological malignancies but absent or expressed at low levels in normal tissues.
- We have validated the NKG2D ligands targeting approach in clinic with two autologous candidates: CYAD-01 and CYAD-02, and one allogeneic candidate: CYAD-101. Overall, NKG2D-based CAR T-cells showed a tolerable safety profile. Some signs of clinical activity were reported in difficult-to-treat patient populations with acute myeloid leukemia or colorectal cancer.
Multispecific CAR approach
A next-generation NKG2D-based multi-specific CAR targeting both NKG2D ligands and another target may help to overcome resistance and immune escape often observed with traditional single targeting approaches.
- With a multi-specific (dual or tandem) CAR, several antigens can be targeted together by the same CAR product so that if there is a loss of one antigen, there are still others that can work to kill the cancer cells
- Much needed alternative in situations where multiple organs are impacted, such as is the case of metastatic and advanced solid cancers
- May move the CAR T-cell landscape beyond B-cell malignancies
- We have developed different NKG2D/CD19 multi-specific CAR T-cells, utilizing both tandem and dual-NKG2D-based CARs that encompass the extracellular domain of the natural NKG2D receptor fused to, or co-expressed with an anti-CD19 CAR